€8.9 million raised
Market capitalisation of €29 million
4th listing of an innovative healthcare company on Euronext Paris in 2022
9th listing on Euronext Paris in 2022
23rd listing on Euronext in 2022
Paris – 6 April 2022 – Euronext today congratulates SMAIO, a healthcare company specialised in complex spinal surgery, on its listing on Euronext Growth Paris (ticker code: ALSMA).
SMAIO (Software, Machines and Adaptative Implants in Orthopaedics) is a Lyon-based company dedicated to the design, manufacturing and marketing of a range of software, implantable devices and services associated with spinal surgery. A pioneer in the use of data to treat spinal pathologies, SMAIO has developed KEOPS, its Big Data management software, which has become a worldwide reference with more than 100,000 patient cases listed. Building on this wide base, SMAIO offers spine surgeons a complete platform of solutions, I-Kontrol, integrating planning, implantable devices and associated services, which enables them to treat spinal pathologies in an efficient, safe and sustainable manner. Following SMAIO's Initial Public Offering (IPO), which includes an investment agreement with NuVasive, a global leader in technological innovations for the spine, it intends to expand the company's business development, particularly in the United States, and to accelerate the execution of its research and development projects in order to strengthen its position in the spinal surgery market, and to pave the way for industrial collaborations to ultimately move towards active robotics and the progressive automation of spinal surgery.
SMAIO was listed through the admission to trading on 6 April 2022 of the 5,228,651 shares making up its equity and of 1,614,195 new shares issued under a Global Offering.
The admission and issue price of SMAIO shares was set at €5.54 per share. Market capitalisation was €29 million on the day of listing. The IPO raised €8.9 million altogether.
Philippe Roussouly, Chief Executive Officer of SMAIO, said: “Our IPO is a major milestone for SMAIO, which aims to establish a new paradigm in spine surgery. SMAIO's differentiated approach, with cutting-edge use of data to treat spinal pathologies and innovative in the field of surgical planning, allows for tailor-made surgery and an optimal, sustainable patient balance. Positioned in a fast-growing market, driven by the need for efficient and reliable solutions, SMAIO's IPO, with the support of its partner NuVasive, aims to accelerate its commercial development, particularly in the United States, the world's largest spine market, while exploiting the immense potential of its database and customised surgical technologies, which will eventually pave the way for active robotics and the progressive automation of spinal surgery.”
Caption: Philippe Roussouly, CEO of SMAIO, and his team rang the bell during a ceremony this morning, in the presence of Guillaume Morelli, Director Listing SME France at Euronext, to celebrate the IPO of the company.
About SMAIO A leader in the use of clinical data and imaging of the spine, SMAIO designs global solutions for spine surgery specialists. The Company has recognized expertise thanks to KEOPS, its Big Data management software that has become a global reference with more than 100,000 patient cases documented. SMAIO offers spine surgeons a comprehensive platform, I-Kontrol, incorporating planning, implants and related services, enabling them to treat spinal pathologies in a safe, effective and lasting way. SMAIO is positioned at the forefront of innovation with the ambition of providing surgeons with the first active robotic solution enabling a high level of performance and repeatability to be systematically achieved. Based in Lyon, France, SMAIO benefits from the skill and expertise of more than 30 highly specialized staff. For further information, please visit our website: www.smaio.com
 The Global Offering was made up of a Public Offering that included a Closed Price Public Offering and a Global Placement with institutional investors in France and other countries.